Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry | Market Weight | YTD Return | |
---|---|---|---|
All Industries | 100.00% | 7.67% | |
Drug Manufacturers - General | 34.34% | 14.51% | |
Healthcare Plans | 13.42% | 0.71% | |
Biotechnology | 12.20% | 7.02% | |
Medical Devices | 11.69% | -0.96% | |
Diagnostics & Research | 11.28% | 6.33% | |
Medical Instruments & Supplies | 6.60% | 7.27% | |
Medical Care Facilities | 3.17% | 25.83% | |
Drug Manufacturers - Specialty & Generic | 2.76% | -0.71% | |
Medical Distribution | 2.33% | 11.98% | |
Health Information Services | 2.06% | 9.26% | |
Pharmaceutical Retailers | 0.15% | -55.25% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
821.19 | 825.82 | 11.42% | Buy | ||||
559.68 | 567.78 | 7.60% | Buy | ||||
159.64 | 158.03 | 5.67% | Buy | ||||
182.17 | 171.49 | 4.75% | Buy | ||||
125.85 | 132.05 | 4.71% | Buy | ||||
594.50 | 628.71 | 3.35% | Buy | ||||
270.09 | 260.90 | 2.88% | Buy | ||||
105.96 | 114.49 | 2.75% | Buy | ||||
334.30 | 295.13 | 2.65% | Buy | ||||
30.18 | 29.24 | 2.52% | Hold |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
149.12 | 39.084B | 0.09% | ||
273.55 | 20.601B | 0.10% | ||
147.03 | 7.363B | 0.45% | ||
100.98 | 7.126B | 0.35% | ||
55.20 | 5.134B | 0.40% |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
224.78 | 47.799B | 0.30% | ||
94.79 | 47.799B | 0.30% | ||
136.92 | 20.601B | 0.10% | ||
97.69 | 14.902B | 0.80% | ||
97.38 | 14.902B | 0.80% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US
RatingPrice TargetAnalyst Report: West Pharmaceutical Services, Inc.
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
RatingPrice TargetAnalyst Report: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
RatingPrice TargetAnalyst Report: Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
RatingPrice Target